Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. The Company's proprietary technology can infuse new life into many existing ophthalmic pharmaceuticals, which can achieve a better, safer therapeutic profile with its technology.Eyenovia is partnering with other specialty pharmaceutical companies who want to differentiate and improve their existing brand therapies to make them the preferred choice for patients, doctors and payers.